SEC Filing | Abbott Laboratories

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Funck Robert E

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

60064

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2013

3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Vice President, Controller

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	60,228	D
Common shares without par value	15,300⁽¹⁾	I	Profit Sharing Trust
Common shares without par value	500⁽²⁾	I	By daughter
Common shares without par value	500⁽²⁾	I	By daughter

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)⁽³⁾	02/18/2006	02/17/2015	Common shares	4,233	22.267	D
Option (right to buy)⁽³⁾	02/18/2007	02/17/2015	Common shares	4,233	22.267	D
Option (right to buy)⁽³⁾	02/18/2008	02/17/2015	Common shares	2,076	22.267	D
Option (right to buy)⁽³⁾	02/17/2007	02/16/2016	Common shares	8,667	21.2194	D
Option (right to buy)⁽³⁾	02/17/2008	02/16/2016	Common shares	8,666	21.2194	D
Option (right to buy)⁽³⁾	02/17/2009	02/16/2016	Common shares	8,667	21.2194	D
Option (right to buy)⁽³⁾	02/16/2008	02/15/2017	Common shares	8,934	25.2461	D
Option (right to buy)⁽³⁾	02/16/2009	02/15/2017	Common shares	8,933	25.2461	D
Option (right to buy)⁽³⁾	02/16/2010	02/15/2017	Common shares	8,933	25.2461	D
Option (right to buy)⁽³⁾	02/15/2009	02/14/2018	Common shares	8,500	26.6973	D
Option (right to buy)⁽³⁾	02/15/2010	02/14/2018	Common shares	8,500	26.6973	D
Option (right to buy)⁽³⁾	02/15/2011	02/14/2018	Common shares	8,500	26.6973	D
Option (right to buy)⁽³⁾	02/20/2010	02/19/2019	Common shares	4,267	26.015	D
Option (right to buy)⁽³⁾	02/20/2011	02/19/2019	Common shares	4,267	26.015	D
Option (right to buy)⁽³⁾	02/20/2012	02/19/2019	Common shares	4,266	26.015	D
Option (right to buy)⁽⁴⁾	02/19/2011	02/18/2020	Common shares	3,234	26.1879	D
Option (right to buy)⁽⁴⁾	02/19/2012	02/18/2020	Common shares	3,233	26.1879	D
Option (right to buy)⁽⁴⁾	02/19/2013	02/18/2020	Common shares	3,233	26.1879	D
Option (right to buy)⁽⁴⁾	02/18/2012	02/17/2021	Common shares	4,100	22.3919	D
Option (right to buy)⁽⁴⁾	02/18/2013	02/17/2021	Common shares	4,100	22.3919	D
Option (right to buy)⁽⁴⁾	02/18/2014	02/17/2021	Common shares	4,100	22.3919	D
Option (right to buy)⁽⁴⁾	02/17/2013	02/16/2022	Common shares	4,800	27.0336	D
Option (right to buy)⁽⁴⁾	02/17/2014	02/16/2022	Common shares	4,800	27.0336	D
Option (right to buy)⁽⁴⁾	02/17/2015	02/16/2022	Common shares	4,800	27.0336	D
Option (right to buy)⁽⁵⁾	08/02/2013	02/19/2014	Common shares	5,715	33.88	D
Option (right to buy)⁽⁵⁾	04/27/2013	02/19/2014	Common shares	2,137	31.6081	D
Option (right to buy)⁽⁴⁾	02/15/2014	02/14/2023	Common shares	21,234	34.94	D
Option (right to buy)⁽⁴⁾	02/15/2015	02/14/2023	Common shares	21,233	34.94	D
Option (right to buy)⁽⁴⁾	02/15/2016	02/14/2023	Common shares	21,233	34.94	D
Option (right to buy)⁽⁵⁾	08/20/2013	02/19/2014	Common shares	1,546	35.08	D

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2013.

2. The reporting person disclaims beneficial ownership of all securities held by his daughter.

3. Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

5. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.

	John A. Berry, Attorney-in-Fact for Robert E. Funck	03/08/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24.1


POWER OF ATTORNEY


The undersigned constitutes and appoints HUBERT L. ALLEN, JOHN A. BERRY
and JESSICA H. PAIK, and each of them individually, as the undersigned's
true and lawful attorney-in-fact and agent, with full power of substitution
and re-substitution, for the undersigned and in the undersigned's name,
place and stead, to prepare and sign any and all Securities and Exchange
Commission ("SEC") Notices of Proposed Sales of Securities pursuant to
Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements
on Forms 3, 4 and 5 as required under Section 16(a) of the Securities
Exchange Act of 1934, including a Form ID and any other documents
necessary to obtain codes and passwords necessary to make electronic
filings, and any amendments to such forms, and to file the same with all
exhibits thereto, and other documents in connection therewith, with the
SEC, granting unto said attorney-in-fact and agent full power and
authority to do and perform each act and thing requisite, necessary or
desirable to be done under said Rule 144 and Section 16(a), as fully
for all intents and purposes as the undersigned might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact
and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect
until the undersigned is no longer required to file Forms 144, 3, 4, or
5 or if earlier, until the undersigned revokes such authorization by
written instructions to the attorney-in-fact.



Date:  January 2, 2013

/s/ Robert E. Funck
Signature of Reporting Person

Robert E. Funck


Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064